Singapore, Sep 02, 2010: New York-based Thomson Reuters, a leading source of intelligent information for businesses and professionals, and Rondaxe Enterprises, a company providing a suite of services that combines expert drug development consulting, in-depth project management leadership, software applications and virtual business development, have announced an agreement that will enable professionals working in the generic drug sector to better estimate the cost of manufacturing active pharmaceutical ingredients (API).

Information on the costs associated with manufacturing APIs is vital for generic drug companies and API manufacturers around the world, which operate in an intensely price competitive market. Choosing the right drugs to develop and launch is imperative and can determine the difference between profitable or unprofitable products.

Under the terms of the arrangement, patent and synthesis route data from Thomson Reuters will be combined with leading cost-of-goods (CoG) modeling tools from Rondaxe. This will allow professionals working in portfolio selection, research and development, as well as process chemists and engineers, to model drug manufacturing processes and to perform cost analysis simulations.

"We are delighted to partner with Rondaxe to strengthen our services to the generic and API manufacturing market," said Claude Bassett, vice president of Specialty Markets at Thomson Reuters. "The partnership enables us to meet a demand from our clients for greater insight into the costs associated with manufacturing an API, which are often the most significant factor in the cost of goods of the finished generic drug."

Ken Shultis, CEO at Rondaxe Enterprises said; "We are excited to bring together our cost-of-goods expertise, augmented by our CoGs software product, with the leading information from Thomson Reuters in order to benefit pharmaceutical and biotech companies around the world."